4D Molecular Therapeutics has announced the appointment of Kristian Humer as Chief Financial Officer, effective immediately. With over 20 years of experience in corporate finance and biotechnology, Humer will oversee the company's financial strategies during a critical transitional phase.
Company Information
Company
4D Molecular Therapeutics
Location
Emeryville, California, United States
About
4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Phase 3 development underway for wet age-related macular degeneration and a second indication in diabetic macular edema. The company’s second candidate, 4D-710, is the first known genetic medicine to achieve successful aerosol-based delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis.
Fundz sees it the moment 4D Molecular Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
EmeryvilleBiotechnologyHealth CareMedicalGeneticsTherapeutics